Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy